What is Global Aminoglycosides Antibiotics Market?
The Global Aminoglycosides Antibiotics Market is a vast and complex field that deals with the production, distribution, and consumption of aminoglycosides antibiotics. These are a class of antibiotics that are used to treat a variety of bacterial infections. The market encompasses a wide range of antibiotics, including Neomycin, Tobramycin, Gentamicin, Amikacin, Etimicin, and others. The market is driven by the increasing prevalence of bacterial infections and the growing need for effective treatments. However, the market is also faced with several challenges, such as the increasing resistance of bacteria to antibiotics and the side effects associated with the use of aminoglycosides. Despite these challenges, the market continues to grow, driven by the ongoing research and development activities in the field of antibiotics.
Neomycin, Tobramycin, Gentamicin, Amikacin, Etimicin, Others in the Global Aminoglycosides Antibiotics Market:
The Global Aminoglycosides Antibiotics Market is not just limited to the production and distribution of antibiotics. It also involves their usage in various settings such as hospitals, clinics, post-care facilities, government and military institutions, and others. In hospitals and clinics, these antibiotics are used to treat patients with severe bacterial infections. In post-care facilities, they are used to prevent infections in patients who have undergone surgery or other medical procedures. In government and military institutions, these antibiotics are used to protect personnel from bacterial infections. Despite the widespread usage of these antibiotics, their use is regulated by strict guidelines to prevent the development of antibiotic resistance.
Hospital, Clinic, Post Care Facility, Government & Military, Others in the Global Aminoglycosides Antibiotics Market:
The outlook for the Global Aminoglycosides Antibiotics Market is positive. In 2022, the market was valued at US$ 1051.5 million and it is expected to reach US$ 1244.9 million by 2029, growing at a compound annual growth rate (CAGR) of 2.4% during the forecast period from 2023 to 2029. The largest share of the market is held by clinics, which accounted for about 35% of the market in 2019. Europe is the largest consumer of aminoglycosides antibiotics, with a market share of nearly 26% in 2019. This growth is driven by the increasing prevalence of bacterial infections and the ongoing research and development activities in the field of antibiotics.
| Report Metric | Details |
| Report Name | Aminoglycosides Antibiotics Market |
| Accounted market size in 2022 | US$ 1051.5 in million |
| Forecasted market size in 2029 | US$ 1244.9 million |
| CAGR | 2.4% |
| Base Year | 2022 |
| Forecasted years | 2023 - 2029 |
| Segment by Type |
|
| Segment by Application |
|
| Consumption by Region |
|
| By Company | Jemicare, Teva, Novartis, Fangyuan-pharma, Aike Pharmaceutical, Cipla, Pfizer, Fresenius Kabi, Sun Pharma, Hikma, Lannett Company |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
